Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Schizophrenia

  Free Subscription


06.06.2022

1 Brain Res
1 Cereb Cortex
1 J Clin Psychiatry
1 J Psychiatry Neurosci
3 Mol Psychiatry
1 Psychiatry Res
1 Psychol Med
4 Schizophr Res


  Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    Brain Res

  1. CURRIE J, Waiter GD, Johnston B, Feltovich N, et al
    Blunted neuroeconomic loss aversion in schizophrenia.
    Brain Res. 2022;1789:147957.
    PubMed         Abstract available


    Cereb Cortex

  2. XU X, Li Q, Qian Y, Cai H, et al
    Genetic mechanisms underlying gray matter volume changes in patients with drug-naive first-episode schizophrenia.
    Cereb Cortex. 2022 May 31. pii: 6595503. doi: 10.1093.
    PubMed         Abstract available


    J Clin Psychiatry

  3. FANG SC, Huang CY, Shao YJ
    Long-term Outcomes of Early Use of Long-Acting Injectable Antipsychotics in Schizophrenia.
    J Clin Psychiatry. 2022;83.
    PubMed         Abstract available


    J Psychiatry Neurosci

  4. WANG L, Yin Y, Feng W, Zhou Y, et al
    Childhood trauma and cognitive deficits in patients with schizophrenia: mediation by orbitofrontal cortex H-shaped sulci volume.
    J Psychiatry Neurosci. 2022;47:E209-E217.
    PubMed         Abstract available


    Mol Psychiatry

  5. KOMATSU H, Onoguchi G, Jerotic S, Kanahara N, et al
    Correction: Retinal layers and associated clinical factors in schizophrenia spectrum disorders: a systematic review and meta-analysis.
    Mol Psychiatry. 2022 May 27. pii: 10.1038/s41380-022-01620.
    PubMed        

  6. MATLIK K, Garton DR, Montano-Rodriguez AR, Olfat S, et al
    Elevated endogenous GDNF induces altered dopamine signalling in mice and correlates with clinical severity in schizophrenia.
    Mol Psychiatry. 2022 May 26. pii: 10.1038/s41380-022-01554.
    PubMed         Abstract available

  7. HYDE J, Carr H, Kelley N, Seneviratne R, et al
    Efficacy of neurostimulation across mental disorders: systematic review and meta-analysis of 208 randomized controlled trials.
    Mol Psychiatry. 2022;27:2709-2719.
    PubMed         Abstract available


    Psychiatry Res

  8. BHATTACHARYYA U, Bhatia T, Deshpande SN, Thelma BK, et al
    Genetic variations in evolutionary accelerated regions disrupt cognition in schizophrenia.
    Psychiatry Res. 2022;314:114586.
    PubMed         Abstract available


    Psychol Med

  9. HOMAN P, Schooler NR, Brunette MF, Rotondi A, et al
    Relapse prevention through health technology program reduces hospitalization in schizophrenia.
    Psychol Med. 2022 May 30:1-7. doi: 10.1017/S0033291722000794.
    PubMed         Abstract available


    Schizophr Res

  10. LIANG L, Heinrichs RW, Liddle PF, Jeon P, et al
    Cortical impoverishment in a stable subgroup of schizophrenia: Validation across various stages of psychosis.
    Schizophr Res. 2022 May 26. pii: S0920-9964(22)00188.
    PubMed         Abstract available

  11. PALOMAR-CIRIA N, Cegla-Schvartzman F, Bello HJ, Martinez-Ales G, et al
    Diagnostic stability of schizophrenia in clinical settings: An observational study of 198,289 patient/years.
    Schizophr Res. 2022;244:81-83.
    PubMed        

  12. SETIEN-SUERO E, Ayesa-Arriola R, Pena J, Crespo-Facorro B, et al
    Longitudinal effects of cannabis use on attentional processes in patients with first episode of psychosis.
    Schizophr Res. 2022;244:71-80.
    PubMed         Abstract available

  13. KURTZ MM
    Kraepelin, schizophrenia and the first biological era in psychiatry.
    Schizophr Res. 2022;244:69-70.
    PubMed        


Thank you for your interest in scientific medicine.


AMEDEO Schizophrenia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: